Patents by Inventor Daniel Carper

Daniel Carper has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PROCESS FOR MAKING A PD-1/PD-L1 INHIBITOR AND SALTS AND CRYSTALLINE FORMS THEREOF
    Publication number: 20240158395
    Abstract: This application relates to processes and intermediates for the preparation of the PD-1/PD-L1 inhibitor (R)-1-((7-cyano-2-(3?-((2-(difluoromethyl)-7-((3-hydroxypyrrolidin-1-yl)methyl)pyrido[3,2-d]pyrimidin-4-yl)amino)-2,2?-dimethyl-[1,1?-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)piperidine-4-carboxylic acid, and salts and crystalline forms thereof, where the PD-1/PD-L1 inhibitor and solid forms and salt forms thereof are useful in the treatment of various diseases including infectious diseases and cancer.
    Type: Application
    Filed: November 21, 2023
    Publication date: May 16, 2024
    Inventors: Dengjin Wang, Daniel Carper, Zhongjiang Jia, Bo Shen, Joseph A. Sclafani, Robert Wilson, Jiacheng Zhou, Osama Suleiman, Mark Wright
  • Process for making a PD-1/PD-L1 inhibitor and salts and crystalline forms thereof
    Patent number: 11866434
    Abstract: This application relates to processes and intermediates for the preparation of the PD-1/PD-L1 inhibitor (R)-1-((7-cyano-2-(3?-((2-(difluoromethyl)-7-((3-hydroxypyrrolidin-1-yl)methyl)pyrido[3,2-d]pyrimidin-4-yl)amino)-2,2?-dimethyl-[1,1?-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)piperidine-4-carboxylic acid, and salts and crystalline forms thereof, where the PD-1/PD-L1 inhibitor and solid forms and salt forms thereof are useful in the treatment of various diseases including infectious diseases and cancer.
    Type: Grant
    Filed: November 5, 2021
    Date of Patent: January 9, 2024
    Assignee: Incyte Corporation
    Inventors: Dengjin Wang, Daniel Carper, Zhongjiang Jia, Bo Shen, Joseph A. Sclafani, Robert Wilson, Jiacheng Zhou, Osama Suleiman, Mark Wright
  • SOLID FORMS, SALTS, AND PROCESSES OF PREPARATION OF A CDK2 INHIBITOR
    Publication number: 20230279004
    Abstract: The present application provides solid forms and salts of a compound of Formula (I): pharmaceutical compositions thereof, methods of treating a disease or disorder associated with CDK2 using the same, and processes of preparing the compound of Formula (I) and the solid forms and salts.
    Type: Application
    Filed: March 7, 2023
    Publication date: September 7, 2023
    Inventors: Joseph A. Sclafani, Daniel Carper, Zhongjiang Jia, Eric Shi, Aibin Zhang, Huaping Zhang, Wenxing Guo
  • PROCESS FOR MAKING A PD-1/PD-L1 INHIBITOR AND SALTS AND CRYSTALLINE FORMS THEREOF
    Publication number: 20220144831
    Abstract: This application relates to processes and intermediates for the preparation of the PD-1/PD-L1 inhibitor (R)-1-((7-cyano-2-(3?-((2-(difluoromethyl)-7-((3-hydroxypyrrolidin-1-yl)methyl)pyrido[3,2-d]pyrimidin-4-yl)amino)-2,2?-dimethyl-[1,1?-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)piperidine-4-carboxylic acid, and salts and crystalline forms thereof, where the PD-1/PD-L1 inhibitor and solid forms and salt forms thereof are useful in the treatment of various diseases including infectious diseases and cancer.
    Type: Application
    Filed: November 5, 2021
    Publication date: May 12, 2022
    Inventors: Dengjin Wang, Daniel Carper, Zhongjiang Jia, Bo Shen, Joseph A. Sclafani, Robert Wilson, Jiacheng Zhou, Osama Suleiman, Mark Wright
  • PROCESSES FOR THE PREPARATION OF ARGINASE INHIBITORS AND THEIR SYNTHETIC INTERMEDIATES
    Publication number: 20220041630
    Abstract: Provided herein are processes and intermediates useful for the preparation of certain compounds, including a compound of formula 21 or formula 22 or a pharmaceutically acceptable salt of either.
    Type: Application
    Filed: July 16, 2021
    Publication date: February 10, 2022
    Applicant: Incyte Corporation
    Inventors: Joseph SCLAFANI, Anthony J. Tomaine, Robert J. Wilson, Daniel Carper, Wayne Han, George Shi, Feiquiang Sun, Guobiao Lu, Jack Liang